KRAS and non-small cell lung carcinoma: Neuropilin 1 (NRP1) modulates TGF-β1-induced epithelial-mesenchymal transition in NSCLC [45], and dual-targeting of EGFR and NRP1 attenuates resistance to EGFR-targeted antibody therapy in KRAS-mutant NSCLC [46].